Insmed reported $69.29M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Cytokinetics USD 5.59M 5.43M Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 69.29M 19.79M Jun/2026
Novartis USD 3.46B 83M Mar/2026
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026